Thailand says on track to use Sinovac vaccine, despite trial data
BANGKOK (Reuters) - Thailand said Wednesday that, while Brazil's data showed 50.4 percent effectiveness, it was still on target to obtain and administer China's Sinovac Biotech coronavirus vaccine from next month.
"There is no impact on our plan right now," said Supakit Sirilak, Director General of the Department of Medical Science, in a briefing on Brazil results.
"We are asking for information directly from Sinovac, so we are waiting for their response to get all the facts," he said.
Thailand, which after the first case a year ago, has recorded 10,991 infections and 67 deaths, has requested 2,000 million Sinovac CoronaVac doses and expects the first 200,000 next month to collect them.
It has also ordered 61 million doses of the AstraZeneca vaccine developed for domestic use and export by Siam Bioscience, a local corporation.
Brazil was the first to inoculate CoronaVac in Indonesia before the massive coronavirus vaccination campaigns began.
On Wednesday, Malaysia said that it would only continue with the supply of Sinovac vaccine if the safety and efficacy requirements of the local regulators were met.
The Food and Drug Administration of Thailand announced on Wednesday that it reviewed all vaccines based on consistency, protection and efficacy.
"The companies requesting approval must provide information that addresses all these points," said Surachoke Tangwiwat, FDA Deputy Secretary General.
Thailand got vaccine registration requests from AstraZeneca and Sinovac on Tuesday.
(Chayut Setboonsarng report and Panarat Thepgumpanat report; Martin Petty editing)